Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T17003
(Former ID: TTDS00225)
|
|||||
| Target Name |
DNA-directed RNA polymerase (RNAP)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] | |||||
| 2 | Mycobacterium infection [ICD-11: 1B10-1B21] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Rifabutin | Drug Info | Approved | Mycobacterium infection | [2] | |
| 2 | Rifapentine | Drug Info | Approved | Tuberculosis | [2] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Rifaximin DR | Drug Info | Phase 3 | Crohn disease | [3] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Rifabutin | Drug Info | [4] | |||
| Binder | [+] 1 Binder drugs | + | ||||
| 1 | Rifapentine | Drug Info | [1] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Rifaximin DR | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. | |||||
| REF 2 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. | |||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.